3-氨基丁酸乙酯 | 5303-65-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基丁酸乙酯
• 英文名称: 3-aminobutanoic acid ethyl ester
• 英文别名: ethyl 3-aminobutyrate；ethyl 3-aminobutanoate
• CAS: 5303-65-1
• 化学式: C₆H₁₃NO₂
• mdl: MFCD00008086
• 分子量: 131.175
• InChiKey: HHIOOBJZIASBFF-UHFFFAOYSA-N

物化性质

• 沸点：
  60-61 °C/13 mmHg (lit.)
• 密度：
  0.894 g/mL at 25 °C (lit.)
• 闪点：
  108 °F
• 溶解度：
  氯仿（微溶）、甲醇（微溶）
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险发生。请避免接触强氧化剂和强还原剂。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  3.2
• 安全说明：
  S16,S26,S36/37/39
• 危险品运输编号：
  UN 3272 3
• 海关编码：
  2922499990
• 危险类别：
  3.2
• 危险品标志：
  Xi
• 危险类别码：
  R10
• 包装等级：
  III
• WGK Germany：
  3
• 危险性防范说明：
  P210,P302+P352,P305+P351+P338
• 危险性描述：
  H225,H315,H319,H335
• 储存条件：
  -20°C时应密闭保存于阴凉干燥处，并确保良好通风。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Ethyl 3-aminobutyrate
CAS-No. : 5303-65-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Flammable liquids (Category 3)
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Flammable. Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H226 Flammable liquid and vapour.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R10 Flammable.
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S16 Keep away from sources of ignition - No smoking.
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C6H13NO2
Molecular Weight : 131,17 g/mol
Component Concentration
Ethyl 3-aminobutyrate
CAS-No. 5303-65-1 -
EC-No. 226-153-5

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
For small (incipient) fires, use media such as "alcohol" foam, dry chemical, or carbon dioxide. For large
fires, apply water from as far as possible. Use very large quantities (flooding) of water applied as a mist or
spray; solid streams of water may be ineffective. Cool all affected containers with flooding quantities of
water.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
Use water spray to cool unopened containers.

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to
form explosive concentrations. Vapours can accumulate in low areas.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and
place in container for disposal according to local regulations (see section 13).
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic
charge.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: -20 °C
Store under nitrogen.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, Flame retardant antistatic protective clothing, The type of protective
equipment must be selected according to the concentration and amount of the dangerous
substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: clear, liquid
Colour: colourless
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 60 - 61 °C at 17 hPa - lit.
boiling range
g) Flash point 42 °C - closed cup
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 0,894 g/mL at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
Heat, flames and sparks.
Incompatible materials
Oxidizing agents, Reducing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting
as this material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal
company. Contact a licensed professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 3272 IMDG: 3272 IATA: 3272
UN proper shipping name
ADR/RID: ESTERS, N.O.S. (Ethyl 3-aminobutyrate)
IMDG: ESTERS, N.O.S. (Ethyl 3-aminobutyrate)
IATA: Esters, n.o.s. (Ethyl 3-aminobutyrate)
Transport hazard class(es)
ADR/RID: 3 IMDG: 3 IATA: 3
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基丁酸乙酯 在 sodium nitrite 作用下， 生成 2-羟基正丁酸乙酯
  参考文献：
  名称：

  Curtius; Mueller, Chemische Berichte, 1904, vol. 37, p. 1265

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨基巴豆酸乙酯 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 反应 6.0h， 生成 3-氨基丁酸乙酯
  参考文献：
  名称：

  使用二氯化碘苯和叠氮化钠直接由1,3-二元醇或3-氨基醇直接合成恶唑烷酮-2-酮和咪唑啉酮-2-酮

  摘要：

  使用碘代二氯二苯甲烷（PhICl 2）和叠氮化钠的相同试剂组合，开发了一种直接，直接由1,3-二醇和3-氨基醇合成恶唑烷-2-酮和咪唑啉-2-酮的通用有效方法。（NaN 3）。

  DOI：

  10.1002/adsc.201300982
• 作为试剂：
  描述：

  (1-methyl-2-ethoxycarbonylethyl)-(2-methyl-2-methoxycarbonylethyl)amine 在 titanium(IV) isopropylate 、 sodium tetrahydroborate 、 3-氨基丁酸乙酯 、 sodium 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 xylene 为溶剂， 反应 45.0h， 生成
  参考文献：
  名称：

  在4-[（（N-取代的-4-哌啶基）芳基氨基] -N，N-二乙基苯甲酰胺的结构-活性关系研究中揭示了影响阿片类δ受体激动剂效力和选择性的因素。

  摘要：

  已经进行了在δ-选择性激动剂如BW373U86（1）和SNC-80（2）中内部氮原子对相邻苄基碳原子的转位影响的研究。已经表明，可以从这种转座获得高亲和力，完全有效和δ类阿片受体选择性化合物。除了需要作为增量地址的N，N-二乙基酰胺基基团外，在研究的化合物组中确定的可促进增量受体亲和力的结构特征还包括哌啶环中3和4位取代基之间的顺式相对立体化学，碱性氮上的反式-crotyl或烯丙基取代基，哌啶环中没有2-甲基，并且在未被N，N-二乙基酰胺基取代的芳基环中没有取代或羟基取代。被发现对mu亲和力很重要的结构特征包括芳基环中的羟基取代，与4-氨基成顺式相对关系的2-甲基以及N-取代基（如环丙基甲基）的存在。还确定了在维持δ受体亲和力的同时可以增加μ受体亲和力，特别是当考虑羟基取代的化合物时。另外，发现由于碳-氮转位而使哌啶化合物相对于哌嗪基配体观察到的更低的μ/δ选择性似乎是由于碳-氮转位而产生

  DOI：

  10.1021/jm000427g

文献信息

• [EN] BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS<br/>[FR] ANALOGUES D’ARYLSPHINGOSINE-1-PHOSPHATE BICYCLIQUES
  申请人：BIOGEN IDEC INC

  公开号：WO2011017561A1

  公开（公告）日：2011-02-10

  Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.

  提供具有在一个或多个SlP受体上拮抗活性的化合物。这些化合物是鞘氨醇类似物，在磷酸化后可以在SlP受体上表现为拮抗剂。
• Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)
  作者：Henning Steinhagen、Michael Gerisch、Joachim Mittendorf、Karl-Heinz Schlemmer、Barbara Albrecht

  DOI：10.1016/s0960-894x(02)00602-9

  日期：2002.11

  A new class of PARP-1 inhibitors, namely substituted fused uracil derivatives were synthesised. Starting from a derivative with an IC(50)=2microM the chemical optimisation program led to compounds with more than a 100-fold increase in potency (IC(50)<20nM). Additionally, physicochemical and pharmacokinetic properties were evaluated. It could be shown that compounds bearing a piperazine or phenyl substituted

  合成了一类新的PARP-1抑制剂，即取代的稠合尿嘧啶衍生物。从IC（50）= 2microM的衍生物开始，化学优化程序导致化合物的效力增加了100倍以上（IC（50）<20nM）。另外，评估了理化和药代动力学性质。可以证明带有哌嗪或苯基取代的βAla-Gly侧链的化合物表现出最佳的整体性能。
• Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha
  申请人：——

  公开号：US20020013341A1

  公开（公告）日：2002-01-31

  The present application describes novel &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, U a , X a , Y a , Z a , R 1 , R 2 , R 3 , R 4 , and R 4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.

  本申请描述了式I的新型β-氨基酸衍生物： 1 或其药用可接受的盐或前药形式，其中A、X、Z、U a 、X a 、Y a 、Z a 、R 1 、R 2 、R 3 、R 4 和R 4a 在本规范中有定义，这些衍生物可用作金属蛋白酶和/或TNF-α抑制剂。
• Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics
  作者：Alexander Hillisch、Kersten M. Gericke、Swen Allerheiligen、Susanne Roehrig、Martina Schaefer、Adrian Tersteegen、Simone Schulz、Philip Lienau、Mark Gnoth、Vera Puetter、Roman C. Hillig、Stefan Heitmeier

  DOI：10.1021/acs.jmedchem.0c01035

  日期：2020.11.12

  Despite extensive research on small molecule thrombin inhibitors for oral application in the past decades, only a single double prodrug with very modest oral bioavailability has reached human therapy as a marketed drug. We have undertaken major efforts to identify neutral, non-prodrug inhibitors. Using a holistic analysis of all available internal data, we were able to build computational models and

  尽管在过去的几十年中对口服的小分子凝血酶抑制剂进行了广泛的研究，但只有一种具有非常适度的口服生物利用度的双前药已作为上市药物进入了人类治疗。我们已做出重大努力，以鉴定中性，非前药抑制剂。通过对所有可用内部数据的整体分析，我们能够建立计算模型，并将其用于选择具有最高口服生物利用度可能性的先导系列。在我们的设计中，我们依靠蛋白质结构知识来解决效价问题，并确定了有利理化特性的小窗口以平衡吸收和代谢稳定性。孕烷X受体的蛋白质结构信息有助于克服持续存在的细胞色素P450 3A4诱导问题。通过设计，合成和测试衍生物，将所选化合物系列优化为高效，中性，非前药凝血酶抑制剂。所得的优化化合物BAY1217224已达到首次临床试验，已经证实了所需的药代动力学特性。
• Inhibitors of CYP 17
  申请人：BOCK Mark G.

  公开号：US20100331326A1

  公开（公告）日：2010-12-30

  The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R 53 , R 54 , p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C 17,20 -lyase inhibitors.

  本发明提供了式(I)和(II)的化合物，或其药用可接受的盐， 其中R 53 ，R 54 ，p，q和n如本文所述定义。本发明的化合物被发现作为17α-羟化酶/C 17,20 -裂解酶抑制剂是有用的。